On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men

Last updated: May 10, 2017
Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Overall Status: Completed

Phase

3

Condition

Aids And Aids Related Infections

Hiv Infections

Hiv/aids

Treatment

N/A

Clinical Study ID

NCT01473472
2011-002645-35
IPERGAY
  • Ages > 18
  • Male
  • Accepts Healthy Volunteers

Study Summary

This phase III, multi-centre, comparative, double-blind, randomized trial on 2 parallel groups is designed to evaluate a strategy for the prevention of HIV infection including "on demand" antiretroviral pre-exposure with Truvada versus placebo, associated with overall prevention (counselling, condoms, sexually transmitted diseases (STD) screening, hepatitis B virus (HBV) and hepatitis A virus (HAV) vaccinations and post-exposure treatment of HIV infection) in men who have sex with men (MSM), exposed to the risk of HIV infection. Indeed recent studies have reported a higher incidence of new HIV infection in MSM as compared to the general population, new approaches to the prevention of HIV infection are, therefore, necessary in order to consider the limits of current strategies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years old

  • Male (or transgender) having sex with men

  • Not infected with HIV-1 or HIV-2

  • Elevated risk of HIV contamination : anal sexual relations with at least 2 differentsexual partners within the past 6 months without the systematic use of a condom

  • Satisfactory kidney function with a clearance of more than 60 mL/min (Cockcroftformula)

  • Alanine aminotransferase (ALT) < 2.5 Upper Limit of Normal (ULN),

  • Neutrophil granulocytes ≥ 1 000/mm3, haemoglobin ≥ 10 g/dL, platelets ≥ 150 000/mm3

  • Negative HBs antigen and negative hepatitis C virus (HCV) serology (or negative HCVPCR if positive serology)

  • Agrees to be contacted personally, if possible by telephone, short message system (SMS) or e-mail

  • Agrees to the constraints imposed by the trial (visits every 2 months)

  • Subjects enrolled in or a beneficiary of a Social Security program (State Medical Aidor Aide médicale de l'Etat (AME) is not a Social Security program).

  • Signature of the informed consent form.

Exclusion

Exclusion Criteria:

  • Subject in a stable and exclusive relationship with a person

  • Systematic use of a condom during sexual relations

  • Expected to go abroad for more than 3 consecutive months or move expected to a citywhere the study is not being conducted.

  • Presence of significant glycosuria or proteinuria > 1+ in the urine dipstick, in theabsence of infection.

  • Presence of significant haematuria or leukocyturia > 2+ in the urine dipstick, in theabsence of infection.

  • History of chronic kidney disease, osteoporosis, osteopaenia

  • History of pathological bone fracture not related to trauma

  • Treatment with Interferon, Interleukin, or antiretrovirals

  • Treatment that could inhibit or compete with the tubular secretion of antiretrovirals

  • Treatment undergoing investigation

  • Intravenous toxicomania

  • Subject who is currently receiving or going to receive a potentially nephrotoxictreatment (long-term anti-inflammatory)

  • Gastro-intestinal disease (or chronic nausea or vomiting) disrupting the absorption oftreatments

  • Positive HBs antigen

  • Positive HCV serology with positive HCV PCR

  • Life-threatening disease (lymphoma) or other serious disease (cardiovascular, renal,pulmonary, unstable diabetes) that could require treatment that could disruptadherence to the treatment

  • Subject potentially non-compliant.

Study Design

Total Participants: 400
Study Start date:
January 01, 2012
Estimated Completion Date:
December 15, 2016

Study Description

The trial has been taken place in two phases in order to ensure the general feasibility of the study:

  • a first enrollment phase for at least 300 participants to ensure the possibility for recruitment in France and Canada and to validate the tools put into place as part of the trial to enroll and follow participants

  • a second phase of 1600 additional participants. This extension phase started on July

The recruitment has been suspended following the recommendations of Data Safety and Monitoring Board (DSMB): the placebo arm has been stopped and Truvada was available for all the participants of the trial since November 2014. The initial protocol was amended and 361 participants were enrolled in the open-label phase. Sub-studies were proposed to the participants:

  • Sub-study on the outcome of participants receiving sofosbuvir/ledipasvir treatment for recent HCV infection (protocol amendment on April 2015)

  • Randomized sub-study to evaluate the efficacy of doxycycline post-exposure prophylaxis on sexually transmitted infections (protocol amendment on July 2015)

  • Sub-study to evaluate Truvada adherence with Medication Event Monitoring System (MEMS) (protocol amendment on December 2015)

  • Sub-study on drugs use and the impact on sexual behavior and Truvada adherence (protocol amendment on December 2015).

Connect with a study center

  • CHUM - Hôpital Hôtel Dieu

    Montréal,
    Canada

    Site Not Available

  • Hôpital de La Croix Rousse

    Lyon,
    France

    Site Not Available

  • CHU Hôtel Dieu

    Nantes, 44093
    France

    Site Not Available

  • Hôpital de l'Archet

    Nice, 06202
    France

    Site Not Available

  • Hôpital Tenon

    Paris, 75
    France

    Site Not Available

  • Hôpital Saint-Louis

    Paris Cedex 10, 75475
    France

    Site Not Available

  • Hôpital Gustave Dron

    Tourcoing, 59208
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.